Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress

Rhea-AI Summary

Incyte (Nasdaq:INCY) announced that its oncology portfolio data will be presented at the EHA 2021 Virtual Congress from June 9-17, 2021. Highlights include the first presentation of Phase 2 study data for parsaclisib in autoimmune hemolytic anemia and real-world data on ruxolitinib. Key abstracts cover studies on ponatinib, ruxolitinib, and combination trials with parsaclisib, emphasizing Incyte's commitment to addressing significant unmet medical needs in oncology.

Positive

• Presentation of Phase 2 study data for parsaclisib in autoimmune hemolytic anemia.
• Real-world data supporting ruxolitinib's efficacy in treating myelofibrosis.
• Multiple key abstracts accepted at the EHA Congress highlight Incyte's oncology portfolio.

Negative

• None.

Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming European Hematology Association (EHA) 2021 Virtual Congress, held virtually from June 9-17, 2021.

“We are pleased that data highlighting the strength of Incyte’s oncology portfolio and partner-sponsored programs will be presented at this year’s EHA Virtual Congress,” said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. “In particular, data being presented at the congress – including the first presentation of data from our Phase 2 study of parsaclisib, our PI3kδ inhibitor, in autoimmune hemolytic anemia; an oral presentation on real-world data for ruxolitinib, our JAK1/JAK2 inhibitor; and an ePoster from our Phase 2 combination study of ruxolitinib and parsaclisib in patients with myelofibrosis – reinforce our commitment to finding solutions for patients with significant unmet medical needs.”

Key abstracts accepted by EHA include:

Oral Presentations

Ponatinib

OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)¹ (Abstract #S153. Session: Response, Resistance and Treatment-Free Remission in CML.)

Ruxolitinib

Efficacy and Safety of Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Vs-Host Disease After Crossover in the Phase 3 REACH2 Study² (Abstract #S236. Session: Stem cell transplantation – GvHD.)

Impact of Ruxolitinib on Survival of Patients with Myelofibrosis in Real World – Update of ERNEST (European Registry for Myeloproliferative Neoplasms) Study² (Abstract #S158. Session: Population based studies in myeloid disorders.)

ePosters

Parsaclisib

Efficacy and Safety Results from an Open-Label Phase 2 Study of Parsaclisib for the Treatment of Autoimmune Hemolytic Anemia (AIHA) (Abstract #EP685. Session: Enzymopathies, Membranopathies and Other Anemias.)

Pharmacologic Inhibition of PI3kδ Reduces Autoantibody Formation and is Efficacious in a Preclinical Model of Autoimmune Hemolytic Anemia (Abstract #EP693. Session: Enzymopathies, Membranopathies and Other Anemias.)

FACIT-Fatigue Subscale Outcomes from an Ongoing Phase 2, Open-Label Study of the Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor Parsaclisib in Patients with Autoimmune Hemolytic Anemia (AIHA) (Abstract #EP706. Session: Enzymopathies, Membranopathies and Other Anemias.)

Ponatinib

French Real-Life Observational Study “TOPASE” Evaluating Safety and Efficacy of Ponatinib Confirms Induction of Deep Molecular Responses in 110 Resistant or Intolerant CML Patients (Abstract #EP679. Session: Chronic Myeloid Leukemia – Clinical.)

Ruxolitinib

An Epidemiological Study of the Cardiovascular Health and Thrombotic Risk Profiles of Patients with Myeloproliferative Neoplasms in Primary Care Across the United Kingdom² (Abstract #EP1090. Session: Myeloproliferative Neoplasms – Clinical.)

Impact of Bone Marrow Fibrosis Grade on Response and Outcome in Patients with Primary Myelofibrosis Treated with Ruxolitinib: A Post-Hoc Analysis of the JUMP Study² (Abstract #EP1092. Session: Myeloproliferative Neoplasms – Clinical.)

Healthcare Resource Utilization in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study² (Abstract #EP1107. Session: Myeloproliferative Neoplasms – Clinical.)

Ruxolitinib-Parsaclisib Combination Studies

Add-On Parsaclisib (a PI3kδ inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study (Abstract #EP1075. Session: Myeloproliferative Neoplasms – Clinical.)

Tafasitamab

Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma³ (Abstract #EP553. Session: Aggressive Non-Hodgkin Lymphoma – Clinical.)

First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed DLBCL³ (Abstract #EP496. Session: Aggressive Non-Hodgkin Lymphoma – Clinical.)

Lenalidomide-Induced Effects on Cell Surface Expression of CD19 and CD20 in DLBCL Cell Lines and Functional Impact on Antibody-Mediated Cytotoxicity³ (Abstract #EP879 . Session: Lymphoma Biology & Translational Research.)

In addition to the presentations noted above, more than 10 publications highlighting data from Incyte’s portfolio will be made available by EHA as publications. Notably, these publications include bioequivalence and bioavailability data for ruxolitinib’s once-daily extended release (XR) formulation – Bioequivalence of 50 mg Once-Daily Ruxolitinib Extended Release (XR) Tablets Compared to 25 mg Twice-Daily Ruxolitinib Immediate Release (IR) Tablets (Abstract #PB1706) and Relative Bioavailability and Dose Linearity of Five Strengths of Ruxolitinib Extended Release (XR) Tablets (Abstract #PB1717).

Full listings for oral presentations and ePoster sessions are available on the EHA website: { "@context": "https://schema.org", "@type": "FAQPage", "name": "Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress FAQs", "mainEntity": [ { "@type": "Question", "name": "What data is Incyte presenting at the EHA 2021 Virtual Congress?", "acceptedAnswer": { "@type": "Answer", "text": "Incyte is presenting data on its oncology portfolio, including Phase 2 study data for parsaclisib and real-world data on ruxolitinib." } }, { "@type": "Question", "name": "When does the EHA 2021 Virtual Congress take place?", "acceptedAnswer": { "@type": "Answer", "text": "The EHA 2021 Virtual Congress is being held from June 9-17, 2021." } }, { "@type": "Question", "name": "Which drugs are highlighted in Incyte's presentations?", "acceptedAnswer": { "@type": "Answer", "text": "Incyte is focusing on parsaclisib, ruxolitinib, and ponatinib in its presentations." } }, { "@type": "Question", "name": "What is the significance of Incyte's presentations at EHA?", "acceptedAnswer": { "@type": "Answer", "text": "The presentations reinforce Incyte's commitment to addressing significant unmet medical needs in oncology." } }, { "@type": "Question", "name": "How many abstracts are being presented by Incyte at EHA?", "acceptedAnswer": { "@type": "Answer", "text": "Multiple key abstracts from Incyte's oncology portfolio have been accepted for presentation at the EHA Congress." } } ] }

FAQ

What data is Incyte presenting at the EHA 2021 Virtual Congress?

Incyte is presenting data on its oncology portfolio, including Phase 2 study data for parsaclisib and real-world data on ruxolitinib.

When does the EHA 2021 Virtual Congress take place?

The EHA 2021 Virtual Congress is being held from June 9-17, 2021.

Which drugs are highlighted in Incyte's presentations?

Incyte is focusing on parsaclisib, ruxolitinib, and ponatinib in its presentations.

What is the significance of Incyte's presentations at EHA?

The presentations reinforce Incyte's commitment to addressing significant unmet medical needs in oncology.

How many abstracts are being presented by Incyte at EHA?

Multiple key abstracts from Incyte's oncology portfolio have been accepted for presentation at the EHA Congress.